PROCEPT BioRobotics Corporation
NGM: PRCTLive Quote
About PROCEPT BioRobotics Corporation
Healthcare
Medical Devices
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
📊 Fundamental Analysis
PROCEPT BioRobotics Corporation demonstrates a profit margin of -31.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported 11.9% revenue growth, which is above average for the Healthcare sector.
Return on Equity (ROE) is -24.9%, which indicates that capital utilization is currently under pressure.
At a current price of $23.20, PRCT currently trades near the bottom of its 52-week range (8%), indicating potential value or weakness (Range: $19.35 - $66.85).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
⚠️
Revenue Growth
Moderate
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$1.64B
Trailing P/E
--
Forward P/E
-26.27
Beta (5Y)
0.93
52W High
$66.85
52W Low
$19.35
Avg Volume
1.66M
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App